Fundraising FoxTriatomic Capital — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer.
BiotechHealthtechMiami, US
Manmeet Soni(Executive Officer, Director)inMahkam Zanganeh(Executive Officer, Director)David Roblin(Executive Officer)inRaymond Spencer(Executive Officer)inRobert W. Duggan(Co-Chief Executive Officer and Chairman of the Board of Directors)David Wurzer(Director)
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inCain McClary(Director)inJonathan Sheena(Director)in
Co-investorsACVC PartnersAndreessen HorowitzIn-Q-TelRaptor GroupAME Cloud VenturesDigitalis Ventures+1 more
Teleo provides a remote command center solution that enables a single operator to supervise multiple machines, improving site productivity and workforce attraction through enhanced safety and comfort, while offering real-time analytics for operational visibility.
Advanced ManufacturingConstruction TechRoboticsSan Francisco, US
Rom Clément(CTO)inVinay Shet(Founder)in
BoardAdam Grosser(Director)inRoger Fradin(Director)
Co-investorsF-Prime CapitalK9 VenturesTrousdale VenturesTrucks VCUP PartnersY Combinator+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.